The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson’s disease
作者： Stefan Hermanowicz , Neal Hermanowicz
DOI: 10.1586/14737175.2016.1158102
关键词:
摘要: Parkinson's disease psychosis (PDP) is a common and often very disturbing component of (PD). PDP consists hallucinations that are mainly visual delusions paranoid nature. These symptoms can be the most troubling disruptive all manifestations disease. Current treatment methods include reduction anti-Parkinson's medications, strategy may worsen motor problems medications prescribed to alleviate, introduction selected antipsychotic carry with them potential for side effects serious consequences. Pimavanserin has been developed studied in clinical trials specifically address submitted U.S. Food Drug Administration its approval this purpose. If granted, we believe evidence efficacy, safety tolerability will position medication as first choice psychosis.
sci-hub.se 参考文章(60)
E. R. Dorsey, R. Constantinescu, J. P. Thompson, K. M. Biglan, R. G. Holloway, K. Kieburtz, F. J. Marshall, B. M. Ravina, G. Schifitto, A. Siderowf, C. M. Tanner, Projected number of people with parkinson disease in the most populous nations, 2005 through 2030 Neurology. ,vol. 68, pp. 384- 386 ,(2007) , 10.1212/01.WNL.0000247740.47667.03
Russell Rosenberg, David J. Seiden, Steven G. Hull, Milton Erman, Howard Schwartz, Christen Anderson, Warren Prosser, William Shanahan, Matilde Sanchez, Emil Chuang, Thomas Roth, APD125, a Selective Serotonin 5-HT2A Receptor Inverse Agonist, Significantly Improves Sleep Maintenance in Primary Insomnia Sleep. ,vol. 31, pp. 1663- 1671 ,(2008) , 10.1093/SLEEP/31.12.1663
K. Krebs-Thomson, S. C. Harvey, N. Nash, K. E. Vanover, M. R. Brann, D. M. Weiner, M. A. Geyer, G. E. Croston, S. B. Powell, D. F. C. Gibson, E. Donohue, C. M. Andersson, U. Hacksell, H. C. Hansen, E. A. Currier, T. A. Spalding, E. S. Burstein, 5-Hydroxytryptamine2A Receptor Inverse Agonists as Antipsychotics Journal of Pharmacology and Experimental Therapeutics. ,vol. 299, pp. 268- 276 ,(2001)
Christopher G. Goetz, Christina L. Vaughan, Jennifer G. Goldman, Glenn T. Stebbins, I finally see what you see: Parkinson's disease visual hallucinations captured with functional neuroimaging Movement Disorders. ,vol. 29, pp. 115- 117 ,(2014) , 10.1002/MDS.25554
Hamad Alzahrani, Annalena Venneri, Cognitive and neuroanatomical correlates of neuropsychiatric symptoms in Parkinson's disease: A systematic review. Journal of the Neurological Sciences. ,vol. 356, pp. 32- 44 ,(2015) , 10.1016/J.JNS.2015.06.037
J. Zoldan, G. Friedberg, M. Livneh, E. Melamed, Psychosis in advanced Parkinson's disease: Treatment with ondansetron, a 5‐HT3 receptor antagonist Neurology. ,vol. 45, pp. 1305- 1308 ,(1995) , 10.1212/WNL.45.7.1305
Herbert Y Meltzer, Roger Mills, Stephen Revell, Hilde Williams, Ann Johnson, Daun Bahr, Joseph H Friedman, Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Neuropsychopharmacology. ,vol. 35, pp. 881- 892 ,(2010) , 10.1038/NPP.2009.176
F Durif, B Debilly, M Galitzky, D Morand, F Viallet, M Borg, S Thobois, E Broussolle, O Rascol, None, Clozapine improves dyskinesias in Parkinson disease A double-blind, placebo-controlled study Neurology. ,vol. 62, pp. 381- 388 ,(2004) , 10.1212/01.WNL.0000110317.52453.6C
Uli Hacksell, Ethan S. Burstein, Krista McFarland, Roger G. Mills, Hilde Williams, On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis Neurochemical Research. ,vol. 39, pp. 2008- 2017 ,(2014) , 10.1007/S11064-014-1293-3
Jaime M. Monti, Serotonin control of sleep-wake behavior. Sleep Medicine Reviews. ,vol. 15, pp. 269- 281 ,(2011) , 10.1016/J.SMRV.2010.11.003